Table 5.

Linear mixed models for CMR derivatives explained by EF at discharge, peak TNT and CK-MB

Outcome	CMR follow-up (N = 560 segments)
	Wall thickening (% AHA-16 segments)			Wall motion (mm AHA-16 segments)			LGE (% transmurality per AHA-16 segments)
	β	P	R 2	β	P	R 2	β	P	R 2
EF at discharge by Echo	0.99 [.38; 1.60]	.002	0.07	0.08 [.02; .13]	.008	0.002	−0.73 [−1.03; −.44]	.001	0.09
Peak TNT	−0.002 [−.003; −.001]	.001	0.07	−0.0002 [−.0003; −.00006]	.003	0.04	0.0013 [.0007; .002]	.001	0.06
Peak CK-MB	−0.06 [−.09; −.03]	.001	0.08	−0.005 [−.008; −.002]	.001	0.05	0.04 [.03; .06]	.001	0.12

Mixed-model regression analyses for routine tests readily available at cardiac units of CMR-derived wall thickening, wall motion, and LGE transmurality per AHA-16 segments

EF, ejection fraction; Echo, echocardiography; TNT troponin T; CK-MB creatine-kinase MB; LGE, late gadolinium enhancement; AHA-16, American Heart Association 16-segment model